EMA Publishes New Guidance for Qualified Person's Declaration on GMP Compliance of API - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Publishes New Guidance for Qualified Person's Declaration on GMP Compliance of API


EMA has published a new guidance template for the qualified person’s declaration concerning GMP compliance of API manufacture.

The QP declaration template provides the basis for demonstrating compliance of the API manufacture with GMP requirements and ensures that the manufacturer has sufficient knowledge on the supply chain.

The objective of this guidance and the QP declaration template is to emphasize the importance of providing a valid declaration, to harmonize the format for the declaration, to forestall questions during assessment, and to enhance the efficiency of the regulatory process, including the timely processing of relevant regulatory submissions. While not mandatory, applicants are strongly encouraged to use the template to facilitate the validation of regulatory submissions and their review.

The QP declaration should be provided in support of applications for marketing authorizations, variation or renewal of a medicinal product(s) authorized in the Community, using EU or national procedures within the scope of the respective Directives.

QP declarations are required from each EEA finished-product manufacturing site and/or from each site of importation/batch certification. A single declaration from one QP from one of the registered finished product or batch-release sites, however, may be sufficient, if its basis is satisfactorily described and supported by technical agreements between these sites.

Source: EMA

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
30%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
8%
All of the above.
45%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics

Click here